Lifecycle Management for Recombinant Protein Production Using Mammalian Cell Culture Technology

被引:1
|
作者
Moran, Enda [1 ]
Gammell, Patrick [1 ]
机构
[1] Pfizer, BioMfg Sci, Dublin 22, Ireland
关键词
Cell culture technology; Post-approval changes; Technology lifecycle management;
D O I
10.1007/10_2013_258
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Product lifecycle management refers to the oversight process and activities carried out to fully realize the commercial potential and value of a product in the marketplace. It is typical for many changes to be introduced to the production processes and testing methods for biopharmaceutical drugs over their lifetime in the commercial marketplace. Technology lifecycle management, as discussed here, refers to the management of the different phases or generations of processes and methods used to make and test the active biopharmaceutical ingredient or drug product, and the adoption of different devices used to present the drug product to patients. The factors to consider when making changes to a commercial biopharmaceutical manufacturing process as part of a technology lifecycle management program are discussed. A case study outlines one approach taken in bringing forward a major process change to a cell culture process for the production of a therapeutic recombinant protein.
引用
收藏
页码:245 / 256
页数:12
相关论文
共 50 条